: Patient cohorts. Schematic illustration of the patients and samples analyzed in the present study. The diagnostic cohort from which the samples were subjected individually to enrichment using the HaloPlex system forms the basis of the study. For the majority of the patients in the diagnostic cohort (n = 163), a matched germline (remission) sample was available and was enriched in pools of ten samples. The core cohort (n =143) contains the patients for whom a matched germline sample was sequenced and a good representation of this sample in the pool had been established by targeted analysis of patient-specific SNPs. For 19 of the patients in the diagnostic cohort, one or two relapse samples were sequenced (n =24 relapse samples in total). A matched germline sample was available for nine of these 19 patients. Ten patients in the diagnostic cohort are neither part of the core cohort nor had a relapse sample available. The extension cohort contains samples sequenced in pools for whom no matched germline sample was available. Each sample was sequenced in two pools, using a design that allowed rare mutations to be assigned to their carrier (Lindqvist et al, manuscript in preparation). The extension cohort was used exclusively for further investigation of genes identified as putatively associated with relapse.
Supplementary
: Mutational signatures detected in the major ALL subtypes and four whole genome sequenced patients. (A) Mutational signatures detected in subtypes of the ALL patients in the core cohort and four whole genome sequenced patients. Whole genome sequenced samples are denoted by "WGS" followed by genetic subtype of each patient. The signatures were inferred from somatic mutations detected in our cohort, and subsequently compared to previously described signatures. Signature S1 represents endogenous C > T substitutions at methylated cytosines, and S3 is the APOBEC signature with a high proportion of C > G substitutions at TpCpA or TpCpT motifs. S2 is characterized by many C > A mutations in a pattern that shows no strong similarity with previously described signatures. (B) Hierarchical clustering of the mutational signatures detected in our data (S1-S3) together with 30 previously described signatures. Description of the known signatures, which were identified by analysis of somatic single nucleotide variants in > 11,000 samples across 40 types of human cancer, is available at http://cancer.sanger.ac.uk/cosmic/signatures. (B) Significant differences in number of Ras mutations were observed between the major BCP-ALL subtypes, with the largest number of Ras mutations in HeH patients and the lowest number in t(12;21) patients. (C) The largest difference in number of Ras mutations was observed between BCP-ALL patients that carry any of the recurrent fusion genes ETV6-RUNX1, BCR-ABL or TCF3-PBX1, which harbored exceptionally few Ras mutations, and the remaining BCP-ALL patients.
